Heart Failure in Type 1 vs Type 2 Diabetes Mellitus: Shared Pathways, Distinct Challenges

TY - JOUR

T1 - Heart Failure in Type 1 vs Type 2 Diabetes Mellitus

T2 - Shared Pathways, Distinct Challenges

AU - Hussain, Muhammad S.

AU - Iyer, Saraswathi

AU - Liew, Yi Jia

AU - Win, Mya Lelt

AU - McCrimmon, Rory J.

AU - Lang, Chim C.

AU - Mordi, Ify R.

N1 - Copyright: © 2026 Muhammad S. Hussain et al. Journal of Diabetes Research published by John Wiley & Sons Ltd.

PY - 2026/5/3

Y1 - 2026/5/3

N2 - Heart failure (HF) is a critical complication in both type 1 (T1D) and type 2 diabetes (T2D) and people with diabetes are at higher risk of developing HF than those without diabetes. The pathophysiology of HF in diabetes often involves diabetic cardiomyopathy, driven by insulin deficiency, insulin resistance (IR), inflammation, and myocardial fibrosis; however, though there are similarities in HF in T1D and T2D, there are also key differences in epidemiology, pathophysiology, treatment, and clinical outcomes. In this review article we will discuss the burden, pathophysiology, and outcomes of HF in diabetes, focusing on differences between T1D and T2D, and the relative unmet need for patients with T1D and HF.

AB - Heart failure (HF) is a critical complication in both type 1 (T1D) and type 2 diabetes (T2D) and people with diabetes are at higher risk of developing HF than those without diabetes. The pathophysiology of HF in diabetes often involves diabetic cardiomyopathy, driven by insulin deficiency, insulin resistance (IR), inflammation, and myocardial fibrosis; however, though there are similarities in HF in T1D and T2D, there are also key differences in epidemiology, pathophysiology, treatment, and clinical outcomes. In this review article we will discuss the burden, pathophysiology, and outcomes of HF in diabetes, focusing on differences between T1D and T2D, and the relative unmet need for patients with T1D and HF.

KW - Type 1 diabetes (T1D)

KW - Type 2 Diabetes (T2D)

KW - Heart Failure (HF)

KW - HFpEF

KW - HFrEF

KW - cardiac microvascular dysfunction (CMD)

KW - SGLT-2i inhibitors and Sotagliflozin

KW - GLP-1RA and Finerenone

KW - heart failure (HF)

KW - GLP-1RA and finerenone

KW - type 2 diabetes (T2D)

KW - type 1 diabetes (T1D)

UR - https://www.scopus.com/pages/publications/105038177138

U2 - 10.1155/jdr/7460084

DO - 10.1155/jdr/7460084

M3 - Review article

SN - 2314-6745

VL - 2026

JO - Journal of Diabetes Research

JF - Journal of Diabetes Research

M1 - 7460084

ER -